Skip to main content
. 2021 Oct 28;22(21):11641. doi: 10.3390/ijms222111641

Figure 4.

Figure 4

Measurement of IFN-α anti-SARS-CoV-2 activity using HeLa cells stably expressing SARS-CoV-2 subreplicon. (A) Schematic of the experimental design of treatments of HeLa cells stably expressing SARS-CoV-2 subreplicon (3C5) with IFN-α and Pyridone 6 for 1 day prior to luciferase and cell viability assays. (B,C) HeLa cells stably expressing SARS-CoV-2 subreplicon were treated with 100–100,000 IU/mL IFN-α in B and simultaneously treated with 10 μM Pyridone 6 in C for 1 day. Luciferase intensity (blue bars) and cell viability (orange lines) were measured and are shown as % of DMSO control. Error bars indicate SD (n = 3). * p < 0.05 and ** p < 0.01 (two-tailed t-test).